[go: up one dir, main page]

USRE37077E1 - Adenosine derivatives and pharmaceutical composition thereof - Google Patents

Adenosine derivatives and pharmaceutical composition thereof Download PDF

Info

Publication number
USRE37077E1
USRE37077E1 US07/997,446 US99744692A USRE37077E US RE37077 E1 USRE37077 E1 US RE37077E1 US 99744692 A US99744692 A US 99744692A US RE37077 E USRE37077 E US RE37077E
Authority
US
United States
Prior art keywords
group
compound
alkyl group
hydrogen
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/997,446
Inventor
Toshio Yamada
Ken-ichi Kageyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Priority to US07/997,446 priority Critical patent/USRE37077E1/en
Application granted granted Critical
Publication of USRE37077E1 publication Critical patent/USRE37077E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to novel adenosine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as an active ingredient.
  • Hypertension is one of the most serious risk factors causing cerebral apoplexy and cardiopathy which are included in the major causes of death.
  • various antihypertensive agents such as diuretics, sympathetic depressant drugs, direct-acting vasodilators, calcium antagonists or angiotensin antagonists have been developed and used for treatment of hypertension.
  • side effects such as bradycardia causing various symptoms such as tiredness, depression of activity, disturbance of cerebral circulation or cerebral ischemia are sometimes observed under the treatment with sympathetic depressant drugs. Therefore, the developments of antihypertensive agents having greater safety and effectiveness are desired.
  • the inventors have found adenosine derivatives having vasodilatively hypotensive effect.
  • FIG. 1 shows a result of hypotensive activity of the present invention compared to another adenosine derivative.
  • adenosine derivatives of the present invention are represented by the following formula (I):
  • X is a cycloalkyl group, an alkyl group having at least one hydroxy group, an alkyl group having at least one phenyl group, a bicycloalkyl group, a naphthylalkyl group, an acenaphthylenylalkyl group or a group of the formula (II) or (III);
  • Z is hydrogen, a hydroxy group or a lower alkoxy group
  • Q is hydrogen or a hydroxy group
  • A is —CH 2 —, —O—, —S— or shows a direct connection
  • Y is —(CH 2 ) n — or shows a direct connection
  • n is an integer of 1 to 3; and the broken line is a double bond or a single bond.
  • R represents a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl.
  • R′ represents hydrogen or a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl.
  • X represents a cycloalkyl group, preferably a cycloalkyl group having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; an alkyl group having at least one hydroxy group, preferably a straight or branched alkyl group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl having one or two hydroxy groups; an alkyl group having at least one phenyl group, preferably a phenylalkyl group or a diphenylalkyl group, for example, a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl having one or two
  • Z represents hydrogen, a hydroxy group or a lower alkoxy group, preferably a straight or branched alkoxy group having 1 to 3 carbon atoms, such as methoxy, ethoxy, propoxy or isopropoxy.
  • Q represents a hydrogen or a hydroxy group.
  • A is —CH 2 —, —O—, —S— or shows a direct connection.
  • Y is —(CH 2 ) n — or shows a direct connection.
  • n is an integer of 1 to 3, and the broken line represents a double bond or a single bond.
  • the adenosine derivatives of the present invention include pharmaceutically acceptable salts of the compounds having above formula (I), for example, salts with alkali metal such as sodium or potassium, with alkaline-earth metal such as calcium or barium, or with other metals such as aluminum, or salts as acid addition with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, citric acid or lactic acid, or salts with an organic base such as ammonia or the like.
  • salts can be prepared from free adenosine derivatives or other salts of these derivatives by a known method.
  • the present invention includes any of the dl, d and 1-isomers.
  • the adenosine derivatives of the present invention can be prepared as follows.
  • TIPDS tetraisopropyldisiloxane
  • a 6-Chloropurine-9-riboside and TIPDS ⁇ Cl 2 (1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane dichloride) are stirred for several hours at room temperature to protect 3′-O- and 5′-O-positions, and then 2′-O-position of the compound protected by TIPDS can be selectively alkylated by an alkylating agent such as methyl iodide, ethyl iodide, propyl iodide or butyl iodide in the presence of catalyst such as silver oxide.
  • an alkylating agent such as methyl iodide, ethyl iodide, propyl iodide or butyl iodide in the presence of catalyst such as silver oxide.
  • a group of —NH—X is introduced to 6-position of the purine by using an amine (X—NH 2 ) containing the group X in the formula (I) according to a conventional method.
  • the protecting group, TIPDS can be removed before or after this replacement reaction between the amine and chloro group at 6-position of the purine or adenosine.
  • the compound of the present invention can be produced by alkylation or an adenosine derivative corresponding to the compound represented by the formula (I), in which R is hydrogen, by an alkylating agent.
  • a diazoparaffin such as diazomethane, diazoethane or diazopropane, can be used as the alkylating agent.
  • the appropriate solvent which does not inhibit the reaction such as 1,2-dimethoxyethane can be preferably used.
  • This O-alkylating reaction can be carried out as follows:
  • reaction mixture is reacted for several minutes to several hours at room temperature in the presence of a catalyst such as p-toluenesulfonic acid.
  • the starting material is dissolved in about 80° C. hot water and an alkylating agent such as diazoparaffin is added thereto, and the reaction mixture is reacted for several hours to a day.
  • the resulting compounds of the present invention can be purified by known methods such as distillation chromatography and recrystallization. Identification is established through, inter alia, melting point (m.p.), elemental analysis, IR, NMR, UV, mass spectrum, etc.
  • test compounds of the present invention which were dissolved or suspended in 0.5% carboxymethylcellulose (C.M.C.) aqueous solution, were orally administered to groups of 2 to 5 ddY-strain male mice, and the LD 50 values were calculated based on the death rate for 14 days thereafter.
  • C.M.C. carboxymethylcellulose
  • test compounds which were dissolved or suspended in 0.5% C.M.C. aqueous solution, were orally administered to groups of 3 spontaneously hypertensive rats (SHR), 33 to 36 weeks old, which were fasted for 20 hours before drug administration. Blood pressure was measured before and 2 hours after the administration of the test drug.
  • SHR spontaneously hypertensive rats
  • FIG. 1 Data show the mean value ⁇ S.E.
  • the adenosine derivatives of the present invention have excellent hypotensive effects at a slight amount of dosage. Furthermore, as shown by FIG. 1, the compounds of the invention, in which characteristically 2-position of sugar part of adenosine is O-alkylated, have longer hypotensive effects compared to the characterless adenosine derivatives which is not O-alkylated. Hypotensive activities of the present invention are kept for long time, so that they have the advantage of cutting down on taking time of drug administration.
  • the compounds of the present invention have excellent antihypertensive effect at oral administration and do not have severe side effect such as bradycardia. Therefore, the compounds of the present invention are not only useful as antihypertensive drugs for oral administration, but also as drugs for various disease caused by hypertension, e.g., cerebrovascular disease such as cerebral hemorrhage, cerebral infarction or subarachnoidal hemorrhage, cardiopathy such as congestive heart failure, myocardial infarction or sudden cardiac death, and renal insufficiency.
  • cerebrovascular disease such as cerebral hemorrhage, cerebral infarction or subarachnoidal hemorrhage
  • cardiopathy such as congestive heart failure, myocardial infarction or sudden cardiac death
  • renal insufficiency e.g., congestive heart failure, myocardial infarction or sudden cardiac death.
  • the compounds of the present invention can be made into pharmaceutical compositions by combination with appropriate medicinal carriers or diluents, and can be formulated into preparations in solid, semisolid, liquid or gaseous form such as tablets, capsules, powders, granules, solutions, suppositories, injections and cataplasms in usual ways for oral or parenteral administrations.
  • the compounds of the present invention can be used in the form of their pharmaceutically acceptable salts, and also can be used alone or in appropriate association, as well as in combination with other pharmaceutically active components.
  • the compounds can be used alone or combined with appropriate additives to make tablets, powders, granules or capsules, e.g. with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
  • conventional additives such as lactose, mannitol, corn starch or potato starch
  • binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins
  • disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose
  • lubricants such as talc or magnesium stearate
  • the compounds of the invention can be made into a suppository by mixing with a variety of bases, e.g. fatty and oily base such as cacao butter, emulsifying base or water-soluble base such as macrogol.
  • bases e.g. fatty and oily base such as cacao butter, emulsifying base or water-soluble base such as macrogol.
  • the compounds of the present invention can be formulated into a preparations for injections for dissolving, suspending or emulsifying in aqueous or nonaqueous solvent, such as distilled water for injection, physiologically saline solution, vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acid or propylene glycol.
  • aqueous or nonaqueous solvent such as distilled water for injection, physiologically saline solution, vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acid or propylene glycol.
  • Cataplasms can be prepared by mixing the compounds with mentha oil, concentrated glycerin, kaolin or other suitable additives.
  • the desirable dose of the compounds of the present invention varies with the subject, form of the drug, method and period of administration. However, in order to obtain desirable effects, generally it is recommended to administer orally 0.1 to 1,000 mg, preferably 0.2 to 500 mg daily. Unit preparations are also recommended for administration in one to several units daily.
  • doses of the compounds in the order of one tenth to one second of the above dose are preferable as daily doses.
  • Prescription example 1 (tablet) Component Content in a tablet (mg) compound of this invention 5 lactose 145 corn starch 40 magnesium stearate 10 Total 200 mg
  • Prescription example 2 (capsule) Component Content in a capsule (mg) compound of this invention 10 lactose 240 Total 250 mg
  • Prescription example 3 (injection) Component Content in an ampule (mg) compound of this invention 5 sodium chloride proper amount distilled water for injection proper amount Total 1 ml

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to novel adenosine derivatives having the formula (I):wherein R is a lower alkyl group; R' is hydrogen or a lower alkyl group; X is a cycloalkyl group, an alkyl group having at least one hydroxy group, an alkyl group having at least one phenyl group, a bicycloalkyl group, a naphthylalkyl group, an acenaphthylenylalkyl group or a group of the formula (II) or (III);Z is hydrogen, a hydroxy group or a lower alkoxy group, Q is hydrogen or a hydroxy group, A is -CH2-, -O-, -S- or shows a direct connection; Y is -(CH2)n- or shows a direct connection; n is an integer of 1 to 3; and the broken line is a double bond or a single bond.and pharmaceutically acceptable salt thereof, which are useful as antihypertensive agents.

Description

This is a Reissue of Ser. No. 07/462,246, filed Jan. 9, 1990, U.S. Pat. No. 4,985,409.
BACKGROUND OF THE INVENTION
The present invention relates to novel adenosine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as an active ingredient.
Hypertension is one of the most serious risk factors causing cerebral apoplexy and cardiopathy which are included in the major causes of death. Thus various antihypertensive agents such as diuretics, sympathetic depressant drugs, direct-acting vasodilators, calcium antagonists or angiotensin antagonists have been developed and used for treatment of hypertension. However, for example, side effects such as bradycardia causing various symptoms such as tiredness, depression of activity, disturbance of cerebral circulation or cerebral ischemia are sometimes observed under the treatment with sympathetic depressant drugs. Therefore, the developments of antihypertensive agents having greater safety and effectiveness are desired. As a result of investigations for orally administrable antihypertensive compounds, the inventors have found adenosine derivatives having vasodilatively hypotensive effect.
SUMMARY OF THE INVENTION
An object of the present invention is to provide novel adenosine derivatives and pharmaceutically acceptable salts thereof having an excellent antihypertensive effect. Another object of the present invention is to provide pharmaceutical compositions containing these adenosine derivatives or pharmaceutically acceptable salts thereof as an active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a result of hypotensive activity of the present invention compared to another adenosine derivative.
DETAILED DESCRIPTION OF THE INVENTION
The adenosine derivatives of the present invention are represented by the following formula (I):
Figure USRE037077-20010227-C00003
wherein R is a lower alkyl group; R′ is hydrogen or a lower alkyl group; X is a cycloalkyl group, an alkyl group having at least one hydroxy group, an alkyl group having at least one phenyl group, a bicycloalkyl group, a naphthylalkyl group, an acenaphthylenylalkyl group or a group of the formula (II) or (III);
Figure USRE037077-20010227-C00004
Z is hydrogen, a hydroxy group or a lower alkoxy group, Q is hydrogen or a hydroxy group, A is —CH2—, —O—, —S— or shows a direct connection; Y is —(CH2)n— or shows a direct connection; n is an integer of 1 to 3; and the broken line is a double bond or a single bond.
In the above formula (I), R represents a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl. R′ represents hydrogen or a lower alkyl group, preferably a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl.
X represents a cycloalkyl group, preferably a cycloalkyl group having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; an alkyl group having at least one hydroxy group, preferably a straight or branched alkyl group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl having one or two hydroxy groups; an alkyl group having at least one phenyl group, preferably a phenylalkyl group or a diphenylalkyl group, for example, a straight or branched alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl having one or two phenyl groups; a bicycloalkyl group, preferably endo- or exo-bicyclo[2,2,1]heptyl group; a naphthylalkyl group, preferably an alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl having a naphthyl group; an acenaphthylenylalkyl group including 1,2-dihydro form thereof, preferably an alkyl group having 1 to 3 carbon atoms, such as methyl, ethyl, propyl or isopropyl having a acenaphthylenyl group; or a group of the above formula (II) or (III).
In the formulas (II) and (III), Z represents hydrogen, a hydroxy group or a lower alkoxy group, preferably a straight or branched alkoxy group having 1 to 3 carbon atoms, such as methoxy, ethoxy, propoxy or isopropoxy. Q represents a hydrogen or a hydroxy group. A is —CH2—, —O—, —S— or shows a direct connection. Y is —(CH2)n— or shows a direct connection. n is an integer of 1 to 3, and the broken line represents a double bond or a single bond.
The adenosine derivatives of the present invention include pharmaceutically acceptable salts of the compounds having above formula (I), for example, salts with alkali metal such as sodium or potassium, with alkaline-earth metal such as calcium or barium, or with other metals such as aluminum, or salts as acid addition with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, citric acid or lactic acid, or salts with an organic base such as ammonia or the like. These salts can be prepared from free adenosine derivatives or other salts of these derivatives by a known method.
When optical isomers exist in the compounds of the invention, the present invention includes any of the dl, d and 1-isomers.
The adenosine derivatives of the present invention can be prepared as follows.
(1) Both 3′-O- and 5′-O-positions of an adenosine derivative are protected by tetraisopropyldisiloxane (TIPDS) group to carry out O-alkylation selectively at the 2′-O-position. A 6-Chloropurine-9-riboside and TIPDS·Cl2 (1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane dichloride) are stirred for several hours at room temperature to protect 3′-O- and 5′-O-positions, and then 2′-O-position of the compound protected by TIPDS can be selectively alkylated by an alkylating agent such as methyl iodide, ethyl iodide, propyl iodide or butyl iodide in the presence of catalyst such as silver oxide.
After the 2′-O-alkylation, a group of —NH—X is introduced to 6-position of the purine by using an amine (X—NH2) containing the group X in the formula (I) according to a conventional method. The protecting group, TIPDS, can be removed before or after this replacement reaction between the amine and chloro group at 6-position of the purine or adenosine.
(2) The compound of the present invention can be produced by alkylation or an adenosine derivative corresponding to the compound represented by the formula (I), in which R is hydrogen, by an alkylating agent. A diazoparaffin, such as diazomethane, diazoethane or diazopropane, can be used as the alkylating agent. The appropriate solvent which does not inhibit the reaction such as 1,2-dimethoxyethane can be preferably used. This O-alkylating reaction can be carried out as follows:
(i) The reaction mixture is reacted for several minutes to several hours at room temperature in the presence of a catalyst such as p-toluenesulfonic acid.
(ii) The starting material is dissolved in about 80° C. hot water and an alkylating agent such as diazoparaffin is added thereto, and the reaction mixture is reacted for several hours to a day.
The resulting compounds of the present invention can be purified by known methods such as distillation chromatography and recrystallization. Identification is established through, inter alia, melting point (m.p.), elemental analysis, IR, NMR, UV, mass spectrum, etc.
EXAMPLE
The following examples, which are illustrative only and not intended to limit the scope of the invention, describe the preparation of the compounds of the present invention.
EXAMPLE 1
(i) 500 ml of acetic anhydride and 500 ml of pyridine were added to 100 g of inosine, and the reaction mixture was stirred for 4 to 10 hours at room temperature. After concentration under reduced pressure, the precipitated crystalline was separated by filtration, washed with water and dried to give 132 g of 2′,3′,5′-O)-triacetylinosine (yield: 98%)
(ii) 50 g of 2′,3′,5′-O-triacetylinosine was dissolved in 400 ml of chloroform. 30 ml of thionyl chloride and 7.2 ml of dimethylformamide were added, and the solution was refluxed with heating for 2 to 4 hours. The reaction mixture was poured into ice cold water, and the separated chloroform layer was washed with saturated aqueous solution of sodium hydrogencarbonate and brine. After drying over sodium sulfate anhydride, the solvent was distilled off. The residue was dissolved in 20% ammonia methanol solution and the container was sealed. After stirring for 3 to 5 hours, the solution was concentrated under reduced pressure. The precipitated crystalline was separated by filtration and dried to give 6-chloro-9-β-D-ribofuranosyl-9H-purine (yield: 60%).
(iii) 20 g of 6-chloro-9-β-D-ribofuranosyl-9H-purine was dissolved in 350 ml of pyridine. 26 g of TIPDS·Cl2 was added thereto and the solution was stirred for 1 to 4 hours at room temperature. The solution was concentrated by dryness and the residue was suspended in water. Benzene was added thereto to extract the resulting product. The benzene layer was washed with 0.1N hydrochloric acid aqueous solution, saturated aqueous solution of sodium hydrogencarbonate and brine. After drying over sodium sulfate anhydride, the solvent was distilled off. The residue was recrystallized from n-hexane to give 24 g of 6-chloro-9-(3′,5′-O-TIPDS-β-D-ribofuranosyl)-9H-purine (yield: 65%).
(iv) 20 g of the resulting product was dissolved in 300 ml of benzene and 200 ml of ethyl iodide, and silver oxide were added thereto to carry out methylation. After reacting for 4 to 10 hours, silver oxide and silver iodide were filtered off and the crude product was purified by silica gel column chromatography to give 6-chloro-9-(2′-O-methyl-3′5′-O-TIPDS-β-D- ribofuranosyl)-9H-purine (yield: 75%).
(v) 16.3 g of the resulting product was dissolved in tetrahydrofuran and 66 ml of 1M solution of tetrabutylammonium fluoride was added. The reaction mixture was stirred for several minutes. The solvent was distilled off and the residue was purified by silica gel column chromatography to give 6-chloro-9-(2′-O-methyl-β-D-ribofuranosyl)-9H-purine.
(vi) To 1.5 g of 6-chloro-9-(2′-O-methyl-β-D-ribofuranosyl)-9H-purine and 510 mg of cyclopentylamine, 1.5 ml of triethylamine and 70 ml of ethanol were added. The solution was refluxed with heating for several ten minutes to 8 hours. After washing the residue with water, methanol was added and the solution was concentrated to dryness again. The residue was recrystallized with ethyl acetate to give N6-cyclopentyl-2′-O-methyladenosine (Compound 1). yield: 80%
NMR(D2O): δ=1.57(4H,m), 1.72(2H,m), 1.94(2H,m), 3.36(3H,s), 3.58(1H.m), 3.70(1H,m), 4.00(1H,m), 4.35(2H,m), 4.53(1H,m), 5.27(1H,d,J=5.37Hz), 5.45(1H,m), 6.02(1H,d,J=5.86Hz), 7.78(1H,m), 8.21(1H,s), 8.39(1H,s)
In the same manner as mentioned above, the following compounds were obtained.
N6-cyclohexyl-2′-O-methyladenosine (Compound 2)
NMR(D2O): δ=1.33(4H,m), 1.61(2H,m), 1.74(2H,m), 1.87(2H,m), 3.30(3H,s), 3.55(1H,m), 3.67(1H,m), 3.97(1H,m), 4.09(1H,m), 4.34(2H,m), 5.25(1H,d,J=4.88Hz), 5.43(1H,m), 6.00(1H,d,J=5.86Hz), 7.65(1H,m), 8.19(1H,s), 8.37(1H,s)
N6-(2,3-dihydroxypropyl)-2′-O-methyladenosine (Compound 3)
NMR(D2O): δ=3.42(3H,s), 3.53(1H,m), 3.61(2H,m), 3.70(1H,dd,J=1.95, 12.7Hz), 3.81(1H,m), 3.90(1H,m), 3.98(1H,m), 4.26(1H,m), 4.41(1H,dd,J=5.37,6.35Hz), 4.56(1H,m), 6.01(1H,d,J=6.35Hz), 8.07(1H,s), 8.20(1H,s)
N6-benzyl-2′-O-methyladenosine (Compound 4)
NMR(D2O): δ=3.32(3H,s), 3.57(1H,m), 3.69(1H,m), 4.00(1H,m), 4.37(2H,m), 4.72(2H,brs), 5.30(1H,d,J=5.4Hz), 5.43(1H,m), 6.04(1H,d,J=5.9Hz), 7.2-7.5(5H,m), 8.22(1H,s), 8.43(1H,s), 8.43(1H,s), 8.51(1H,s)
N6-(2,2-diphenylethyl)-2′-O-methyladenosine (Compound 5)
m.p.: 173.5°-175° C.
NMR(D2O): δ=3.30(3H,s), 3.56(1H,m), 3.66(1H,m), 3.97(1H,m), 4.12(2H,m), 4.34(2H,m), 4.59(1H.m), 5.25(1H,d,J=3.42Hz), 5.35(1H,t,J=5.37Hz), 5.99(1H,d,J=5.86Hz), 7.10(7.40(10H,m), 7.84(1H,m), 8.28(1H,s), 8.33(1H,s)
N6-(exo-dicyclo[2,2,1]heptyl)-2′-O-methyladenosine (Compound 6)
NMR(D2O): δ=1.10-1.40(4H,m), 1.45(2H,m), 1.64(2H,m), 2.23(2H,m), 3.31(3H,s), 3.57(1H,m), 3.67(1H,m), 3.99(1H,m), 4.38(3H,m), 5.30(1H,d,J=4.9Hz), 5.47(1H,m), 6.02(1H,d,J=5.9Hz), 7.68(1H,d,J=7.3Hz), 8.25(1H,s), 8.40(1H,s)
N6-(endo-dicyclo[2,2,1]heptyl)-2′-O-methyladenosine (Compound 7)
NMR(D2O): δ=1.20-1.50(6H,m), 1.64(1H,m), 1.91(1H,m), 2.18(1H,m), 2.52(1H,m), 3.32(3H,s), 3.59(1H,m), 3.69(1H,m), 4.01(1H,m), 4.37(3H,m), 5.31(1H,d,J=4.7Hz), 5.47(1H,m), 6.02(1H,d,J=5.9Hz), 7.88(1H,s), 8.23(1H,s), 8.42(1H,s)
N6-(1-naphthyl)methyl-2′-O-methyladenosine (Compound 8)
m.p.: 184.5°-185.5° C.
NMR(D2O): δ=3.32(3H,s), 3.56(1H,m), 3.69(1H,m), 3.99(1H,m), 4.35(1H,m), 4.39(1H,m), 5.20(2H,m), 5.27(1H,d,J=4.88Hz), 5.37(1H,m), 6.04(1H,d,J=6.35Hz), 7.44(2H,m), 7.55(2H,m), 7.81(1H,d,J=9.28Hz), 7.94(1H,d,J=9.28Hz), 8.22(2H,m), 8.43(1H,s), 8.50(1H,m)
N6-(1-acenaphthylene)methyl-2′-O-methyladenosine (Compound 9)
NMR(D2O): δ=3.36(3H,s), 3.58(1H,m), 3.70(1H,m), 4.00(1H,m), 4.36(1H,m), 4.40(1H,m), 5.00(2H,m), 5.29(1H,d,J=5.4Hz), 5.41(1H,m), 6.05(1H,d,J=6.8Hz), 7.63(1H,d,J=6.4Hz), 7.80(1H,d,J=7.8Hz), 7.87(1H,d,J=8.3Hz), 7.91(1H,d,J=6.4Hz), 8.28(1H,s), 8.44(1H,s), 8.52(1H,m)
N6-(1,2-dihydro-1-acenaphthylenyl)methyl-2′-O-methyladenosine (Compound 10)
NMR(D2O): δ=3.33(3H,s), 3.47(2H,m), 3.60(1H,m), 3.69(2H,m), 3.94(1H,m), 4.01(1H,m), 4.16(1H,m), 4.36(1H,m), 4.40(1H,m), 5.29(1H,d,J=5.4Hz), 5.41(1H,m), 6.04(1H,d,J=5.9Hz), 7.34(1H,m), 7.47(1H,t,J=7.8Hz), 7.65(1H,t,J=8.8Hz), 8.27(2H,m), 8.44(1H,s)
N6-(2,3-dihydro-1H-indene-1-yl)-2′-O-methyladenosine (Compound 11)
NMR(D2O): δ=2.12(1H,m), 2.48(1H,m), 2.85(1H,m), 3.02(1H,m), 3.33(3H,m), 3.59(1H,m), 3.69(1H,m), 4.00(1H,m), 4.38(2H,m), 5.31(1H,d,J=4.39Hz), 5.44(1H,t,J=5.37Hz), 5.92(1H,m), 6.04(1H,d,J=5.86Hz), 7.10-7.30(4H,m), 8.17(1H,m), 8.28(1H,s), 8.41(1H,s)
N6-(2,3-dihydro-1H-indene-2-yl)-2′-O-methyladenosine (Compound 12)
m.p.: 139°-141° C.
NMR(D2O): δ=3.02(2H,m), 3.27(2H,m), 3.31(3H,s), 3.56(1H,m), 3.68(1H,m), 3.99(1H,m), 4.35(2H,m), 4.97(1H,m), 5.30(1H,m), 5.42(1H,m), 6.02(1H,d,J=5.86Hz), 7.14(2H,m), 7.22(2H,m), 8.12(1H,m), 8.26(1H,s), 8.40(1H,s)
N6-(2,3-dihydro-1H-indene-1-yl)methyl-2′-O-methyladenosine (Compound 13)
NMR(D2O): δ=1.89(1H,m), 2.16(1H,m), 2.78(1H,m), 2.92(1H,m), 3.33(1H,s), 3.58(3H,m), 3.70(1H,m), 3.84(1H,m), 4.01(1H,m), 4.38(2H,m), 5.29(1H,d,J=4.9Hz), 5.43(1H,m), 6.04(1H,d,J=6.4Hz), 7.14(1H,m), 7.23(1H,m), 7.29(1H,m), 8.08(1H,m), 8.25(1H,s), 8.42(1H,s)
N6-(3H-indene-1-yl)methyl-2′-O-methyladenosine (Compound 14)
NMR(D2O): δ=3.32(3H,s), 3.32(2H,m), 3.57(1H,m), 3.69(1H,m), 4.00(1H,m), 4.36(1H,m), 4.39(1H,m), 4.69(2H,m), 5.29(1H,d,J=4.9Hz), 5.41(1H,m), 6.03(1H,d,J=5.9Hz), 6.35(1H,m), 7.19(1H,t,J=7.3Hz), 7.27(1H,t,J=7.3Hz), 7.46(1H,d,J=7.3Hz), 7.52(1H,d,J=7.3Hz), 8.25(1H,s), 8.34(1H,s), 8.42(1H,s)
N6-(5-methoxy-2,3-dihydro-1H-indene-1-yl)-2′-O-methyladenosine (Compound 15)
NMR(D2O): δ=2.14(1H,m), 2.51(1H,m), 2.81(1H,m), 3.01(1H,m), 3.33(1H,s), 3.57(1H,m), 3.70(1H,m), 3.72(3H,s), 4.00(1H,m), 4.37(1H,m), 4.40(1H,m), 5.27(1H,d,J=4.9Hz), 5.42(1H,m), 5.85(1H,m), 6.04(1H,d,J=5.9Hz), 6.69(1H,dd,J=1.9, 8.8Hz), 6.83(1H,d,J=1.9Hz), 7.09(1H,m), 8.08(1H,m), 8.28(1H,s), 8.40(1H,s)
N6-(1-tetrahydronaphthyl)-2′-O-methyladenosine (Compound 16)
m.p.: 174°-174.3° C.
NMR(D2O): δ=1.77(1H,m), 2.01(3H.m), 2.77(2H,m), 3.34(3H,s), 3.59(1H,m), 3.69(1H,m), 4.00(1H,m), 4.33(1H,s), 4.41(1H,m), 5.28(1H,d,J=5.37HZ), 5.42(1H,m), 5.64(1H,m), 6.04(1H,d,J=5.86Hz), 7.11(4H,m), 8.11(1H,m), 8.27(1H,s), 8.40(1H,s)
N6-(2-tetrahydronaphthyl)-2′-O-methyladenosine (Compound 17)
m.p.: 124.5°-125° C.
NMR(D2O): δ=1.85(1H,m), 2.09(1H,m), 2.89(3H,m), 3.08(1H,m), 3.32(1H,m), 3.58(1H,m), 3.68(1H,m), 3.99(1H,m), 4.34(1H,m), 4.37(1H,m), 4.51(1H,m), 5.26(1H,d,J=4.88Hz), 5.40(1H,m), 6.02(1H,d,J=5.86Hz), 7.09(4H,m), 7.86(1H,m), 8.23(1H,s), 8.40(1H,s)
N6-(3,4-dihydro-1-naphthyl)methyl-2′-O-methyladenosine (Compound 18)
NMR(D2O): δ=2.20(2H,m), 2.68(2H,t,J=7.8Hz), 3.33(3H,s), 3.70(1H,m), 4.01(1H,m), 4.37(1H,m), 4.40(1H,m), 4.54(2H,m), 5.29(1H,d,J=4.9Hz), 5.43(1H,m), 5.98(1H,m), 6.04(1H,d,J=5.9Hz), 7.16(3H,m), 7.35(1H,m), 8.07(1H,m), 8.27(1H,s), 8.42(1H,s)
N6-(5-hydroxy-1-tetrahydronaphthyl)-2′-O-methyladenosine (Compond 19)
NMR(D2O): δ=1.73(1H,m), 1.94(3H,m), 2.55(2H,m), 3.33(3H,s), 3.57(1H,m), 3.69(1H,m), 4.00(1H,m), 4.36(1H,m), 4.40(1H,m), 5.27(1H,d,J=5.4Hz), 5.41(1H,m), 5.60(1H,m), 6.03(1H,d,J=5.9Hz), 6.64(2H,m), 6.88(1H,t,J=8Hz), 7.99(1H,m), 8.26(1H,s), 8.39(1H,s), 9.24(1H,s)
N6-(1-hydroxy-1-tetrahydronaphthyl)methyl-2′-O-methyladenosine (Compound 20)
NMR(D2O): δ=1.68(1H,m), 1.77(1H,m), 1.86(1H,m), 1.99(1H,m), 2.74(2H,m), 3.33(3H,s), 3.57(2H,m), 3.70(1H,m), 4.00(2H,m), 4.38(2H,m), 5.30(1H,d,J=4.9HZ), 5.39(1H,m), 5.66(1H,m), 6.04(1H,d,J=5.9Hz), 7.07(1H,m), 7.16(2H,m), 7.37(1H,m), 7.60(1H,m), 8.24(1H,s), 8.45(1H,s)
N6-(5-methoxy-1-tetrahydronaphthyl)-2′-O-methyladenosine (Compound 21)
NMR(D2O): δ=1.73(1H,m), 1.94(3H,m), 2.63(2.63H,m), 3.34(3H,s), 3.59(1H,m), 3.70(1H,m), 3.78(3H,s), 4.01(1H,m), 4.37(1H,m), 4.40(1H,m), 5.28(1H,d,J=5.4Hz), 5.41(1H,m), 5.63(1H,m), 6.04(1H,d,J=5.9Hz), 6.79(1H,m), 6.80(1H,d,J=8.3Hz), 7.07(1H,t,J=8.3Hz), 8.05(1H,m), 8.27(1H,s), 8.40(1H,s)
N6-(6-methoxy-1-tetrahydronaphthyl)-2′-O-methyladenosine (Compound 22)
NMR(D2O): δ=1.74(1H,m), 1.97(3H,m), 2.74(2H,m), 3.34(3H,s), 3.57(1H,m), 3.70(3H,s), 3.70(1H,m), 4.01(1H,m), 4.36(1H,m), 4.39(1H,M), 5.27(1H,d,J=5.9Hz), 5.42(1H,m), 5.56(1H,m), 6.04(1H,d,J=5.9Hz), 6.66(1H,m), 6.68(1H,m), 7.07(1H,m), 7.96(1H,m), 8.27(1H,s), 8.39(1H,s)
N6-(7-methoxy-1-tetrahydronaphthyl)-2′-O-methyladenosine (Compound 23)
NMR(D2O): δ=1.74(1H,m), 1.96(3H,m), 2.70(2H,m), 3.34(3H,s), 3.60(3H,s), 3.58(1H,m), 3.70(1H,m), 4.00(1H,m), 4.37(1H,m), 4.40(1H,m), 5.28(1H,d,J=5.4Hz), 5.40(1H,m), 5.58(1H,m), 6.04(1H,d,J=5.9Hz), 6.71(1H,m), 6.76(1H,dd,J=2.9, 8.7Hz), 7.03(1H,d,J=8.7Hz), 8.09(1H,m), 8.28(1H,s), 8.41(1H,s)
N6-(4-chromanyl)-2′-O-methyladenosine (Compound 24)
m.p.: 196°-196.2° C.
NMR(D2O): δ=2.16(2H,m), 3.33(3H,m), 3.56(1H,m), 3.70(1H,m), 3.99(1H,m), 4.23(1H,m), 4.35(3H,m), 5.28(1H,d,J=4.88Hz), 5.39(1H,m), 5.69(1H,m), 6.04(1H,d,J=5.86Hz), 6.79(2H,m), 7.13(2H,m), 8.29(2H,m), 8.43(1H,s)
N6-(4-thiochromanyl)-2′-O-methyladenosine (Compound 25)
NMR(D2O): δ=2.24(1H,m), 2.32(1H,m), 3.13(1H,m), 3.18((1H,m), 3.33(3H,s), 3.57(1H,m), 3.69(1H,m), 3.99(1H,m), 4.35(1H,m), 4.39(1H,m), 5.27(1H,d,J=5.4Hz), 5.37(1H,m), 5.64(1H,m), 6.04(1H,d,J=5.9Hz), 6.99(1H,m), 7.12(1H,m), 7.19(1H,m), 8.26(1H,s), 8.35(1H,s), 8.43(1H,s)
N6-(9-fluorenyl)-2′-O-methyladenosine (Compound 26)
m.p.: 189°-190° C.
NMR(D2O): δ=3.35(3H,s), 3.59(1H,m), 3.71(1H,m), 4.01(1H,m), 4.37(1H,m), 4.421H,m), 5.29(3H,m), 5.38(1H,m), 6.06(1H,d,J=6.35Hz), 7.28(2H,t,J=7.81Hz), 6.69(1H,m), 7.41(2H,t,J=7.81Hz), 7.49(2H,m), 7.86(2H,d,J=7.32Hz), 8.42(1H,m), 8.47(1H,s),
N6-(9-fluorenyl)methyl-2′-O-methyladenosine (Compound 27)
NMR(D2O): δ=3.35(3H,s), 3.53(1H,m), 3.63(1H,m), 3.95(2H,m), 4.21(1H,m), 4.30(2H,m), 5.27(1H,d,J=3.9Hz), 5.35(1H,m), 5.96(1H,d,J=5.2Hz), 6.61(1H,d,J=7.3Hz), 7.02(2H,t,J=7.3Hz), 7.20(2H,t,J=7.3Hz), 7.47(1H,d,J=7.3Hz), 7.67(1H,d,J=7.3Hz), 7.81(1H,d,J=7.3Hz), 7.94(1H,d,J=7.3Hz), 8.08(1H,s), 8.33(1H,s)
N6-(9-hydroxy-9-fluorenyl)methyl-2′-O-methyladenosine (Compound 28)
NMR(D2O): δ=3.37(3H,s), 3.58(1H,m), 3.67(1H,m), 3.99(3H,m), 4.37(2H,m), 5.29(1H,d,J=4.9Hz), 5.37(1H,t,J=5.4Hz), 6.02(1H,d,J=6.4Hz), 6.40(1H,s), 7.24(2H,m), 7.35(2H,t,J=7.3Hz), 7.53(2H,d,J=6.8Hz), 7.76(2H,d,J=7.3Hz), 8.12(1H,s), 8.45(1H,s)
N6-(9-xanthenyl)methyl-2′-O-methyladenosine (Compound 29)
NMR(D2O): δ=3.32(3H,s), 3.61(2H,m), 3.69(1H,m), 4.00(1H,m), 4.36(4H,m), 5.31(1H,d,J=3.9Hz), 5.43(1H,m), 6.04(1H,d,J=5.4Hz), 7.00-7.40(8H,m), 8.01(1H,m), 8.20(1H,s), 8.43(1H,s)
EXAMPLE 2
50 g of 5-aminoimidazol-4-carboxamide-1-ribofuranoside was dissolved in 2 l of ethanol solution of sodium ethoxide. 20 ml of ethyl acetate was added, and the reaction mixture was heated for 3 hours at 120° C. After cooling, 1 l of water was added. The solution was neutralized by ion-exchange resin and concentrated to dryness. 200 ml of acetic anhydride and 250 ml of pyridine were added and the solution was stirred at room temperature. The solution was concentrated to dryness and the residue was separated with chloroform/water. The chloroform layer was washed with 0.1 N hydrochloric acid aqueous solution, saturated aqueous solution of sodium hydrogencarbonate and brine, and then dried over sodium sulfate anhydride.
And in the same manner as Example 1 (ii) to (v), 6-chloro-2-methyl-9-(2′-O-methyl-β-D-ribofuranosyl)-9H-purine was obtained.
The resulting product and aminocyclohexane were reacted in the same manner as Example 1 (vi) to give
N6cyclohexyl-2,2′-O-dimethyladenosine (Compound 30).
NMR(D2O): δ=1.33(4H,m), 1.61(2H,,m), 1.74(2H,m), 1.87(2H,m), 2.40(3H,s), 3.28(3H,s), 3.57(1H,m), 3.67(1H,m), 4.00(1H,m), 4.09(1H,m), 4.34(2H,m), 5.26(1H,d,J=4.39Hz), 5.75(1H,m), 5.96(1H,d,J=6.35Hz), 2.51(1H,m), 8.26(1H,s)
The following descriptions serve to illustrative pharmaceutical studies of the compounds of the present invention.
(1) Acute toxicity test
The test compounds of the present invention, which were dissolved or suspended in 0.5% carboxymethylcellulose (C.M.C.) aqueous solution, were orally administered to groups of 2 to 5 ddY-strain male mice, and the LD50 values were calculated based on the death rate for 14 days thereafter. An example of the results is shown in Table 1.
TABLE 1
Test Compound LD50 (mg/kg)
Compound 8 230
Compound 11 450
Compound 16 230
Compound 24 250
(2) Antihypertensive activity
The test compounds, which were dissolved or suspended in 0.5% C.M.C. aqueous solution, were orally administered to groups of 3 spontaneously hypertensive rats (SHR), 33 to 36 weeks old, which were fasted for 20 hours before drug administration. Blood pressure was measured before and 2 hours after the administration of the test drug. An example of the results is shown in Table 2 and FIG. 1. Data show the mean value ±S.E.
TABLE 2
Test Dosage Blood pressure (mmHg)
Compound (mg/kg) Before 2 hrs (Decrease %)
Control — 223 ± 3 221 ± 6  (0.9 ± 2.6)
Compound 1 0.3  228 ± 12  98 ± 8 (56.5 ± 5.5)
Compound 2 0.3  206 ± 12 129 ± 8 (37.5 ± 1.7)
Compound 5 3 211 ± 5  148 ± 19 (30.0 ± 8.4)
Compound 8 3 206 ± 4 140 ± 7 (36.2 ± 5.7)
Compound 11 3  225 ± 11  133 ± 21 (41.3 ± 7.0)
Compound 12 10  213 ± 12 164 ± 5 (22.7 ± 2.2)
Compound 16 3 206 ± 1 109 ± 9 (47.2 ± 4.2)
Compound 17 3 219 ± 3 187 ± 7 (14.5 ± 1.9)
Compound 24 1 218 ± 7  98 ± 15 (55.4 ± 5.6)
As shown by the above-mentioned results, the adenosine derivatives of the present invention have excellent hypotensive effects at a slight amount of dosage. Furthermore, as shown by FIG. 1, the compounds of the invention, in which characteristically 2-position of sugar part of adenosine is O-alkylated, have longer hypotensive effects compared to the characterless adenosine derivatives which is not O-alkylated. Hypotensive activities of the present invention are kept for long time, so that they have the advantage of cutting down on taking time of drug administration.
Thus the compounds of the present invention have excellent antihypertensive effect at oral administration and do not have severe side effect such as bradycardia. Therefore, the compounds of the present invention are not only useful as antihypertensive drugs for oral administration, but also as drugs for various disease caused by hypertension, e.g., cerebrovascular disease such as cerebral hemorrhage, cerebral infarction or subarachnoidal hemorrhage, cardiopathy such as congestive heart failure, myocardial infarction or sudden cardiac death, and renal insufficiency.
The compounds of the present invention can be made into pharmaceutical compositions by combination with appropriate medicinal carriers or diluents, and can be formulated into preparations in solid, semisolid, liquid or gaseous form such as tablets, capsules, powders, granules, solutions, suppositories, injections and cataplasms in usual ways for oral or parenteral administrations.
In pharmaceutical dosage forms, the compounds of the present invention can be used in the form of their pharmaceutically acceptable salts, and also can be used alone or in appropriate association, as well as in combination with other pharmaceutically active components.
In case of oral preparations, the compounds can be used alone or combined with appropriate additives to make tablets, powders, granules or capsules, e.g. with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.
Furthermore, the compounds of the invention can be made into a suppository by mixing with a variety of bases, e.g. fatty and oily base such as cacao butter, emulsifying base or water-soluble base such as macrogol.
The compounds of the present invention can be formulated into a preparations for injections for dissolving, suspending or emulsifying in aqueous or nonaqueous solvent, such as distilled water for injection, physiologically saline solution, vegetable oil, synthetic aliphatic acid glycerides, esters of higher aliphatic acid or propylene glycol.
Cataplasms can be prepared by mixing the compounds with mentha oil, concentrated glycerin, kaolin or other suitable additives.
The desirable dose of the compounds of the present invention varies with the subject, form of the drug, method and period of administration. However, in order to obtain desirable effects, generally it is recommended to administer orally 0.1 to 1,000 mg, preferably 0.2 to 500 mg daily. Unit preparations are also recommended for administration in one to several units daily.
In case of parenteral administrations e.g. injections, doses of the compounds in the order of one tenth to one second of the above dose are preferable as daily doses.
Some prescriptions of the pharmaceutical compositions are shown below as examples which contain the compounds of the present invention as active ingredients.
Prescription example 1 (tablet)
Component Content in a tablet (mg)
compound of this invention 5
lactose 145
corn starch 40
magnesium stearate 10
Total 200 mg
Prescription example 2 (capsule)
Component Content in a capsule (mg)
compound of this invention 10
lactose 240
Total 250 mg
Prescription example 3 (injection)
Component Content in an ampule (mg)
compound of this invention 5  
sodium chloride proper amount
distilled water for injection proper amount
Total
1 ml

Claims (4)

What is claimed is:
1. An adenosine compound of the formula (I):
Figure USRE037077-20010227-C00005
wherein R is a C1-3 alkyl group; R′ is hydrogen or a C1-3 alkyl group; X is a C3-8 cycloalkyl group, a C1-4 alkyl group having one or two hydroxy groups, a C1-3 group havine one or two phenyl groups, a bicycloheptyl group, a C1-3 alkyl group having a naphthyl group, a C1-3 alkyl group having an acenaphthylenyl group, or a group of the formula (II) or (III);
Figure USRE037077-20010227-C00006
wherein Z is hydrogen, a hydroxy group or a C1-3 alkoxy group, Q is hydrogen or a hydroxy group, A is —CH2—, —o—, —s— or shows a direct connection; Y is —(CH2)n— or shows a direct connection; n is an integer of 1 to 3; and the broken line represents the presence or absence of a second bond, or a pharmaceutically acceptable salt thereof.
2. An adenosine compound or a salt thereof according to claim 1 wherein R′ is hydrogen.
3. A pharmaceutical composition comprising as an active ingredient an effective amount of an adenosine compound or salt thereof of claim 1, together with a pharmaceutically acceptable carrier.
4. A method for treating hypertension in a mammal which comprises administering to the mammal an antihypertensive effective amount of at least one adenosine compound or pharmaceutically acceptable salt thereof of claim 1.
US07/997,446 1989-01-11 1992-12-28 Adenosine derivatives and pharmaceutical composition thereof Expired - Lifetime USRE37077E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/997,446 USRE37077E1 (en) 1989-01-11 1992-12-28 Adenosine derivatives and pharmaceutical composition thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1-5658 1989-01-11
JP1005658A JPH0725785B2 (en) 1989-01-11 1989-01-11 Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient
US07/462,246 US4985409A (en) 1989-01-11 1990-01-09 Adenosine derivatives and pharmaceutical composition thereof
US07/997,446 USRE37077E1 (en) 1989-01-11 1992-12-28 Adenosine derivatives and pharmaceutical composition thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/462,246 Reissue US4985409A (en) 1989-01-11 1990-01-09 Adenosine derivatives and pharmaceutical composition thereof

Publications (1)

Publication Number Publication Date
USRE37077E1 true USRE37077E1 (en) 2001-02-27

Family

ID=11617214

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/462,246 Ceased US4985409A (en) 1989-01-11 1990-01-09 Adenosine derivatives and pharmaceutical composition thereof
US07/997,446 Expired - Lifetime USRE37077E1 (en) 1989-01-11 1992-12-28 Adenosine derivatives and pharmaceutical composition thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/462,246 Ceased US4985409A (en) 1989-01-11 1990-01-09 Adenosine derivatives and pharmaceutical composition thereof

Country Status (7)

Country Link
US (2) US4985409A (en)
EP (1) EP0378518B1 (en)
JP (1) JPH0725785B2 (en)
AT (1) ATE112285T1 (en)
DE (1) DE69012840T2 (en)
DK (1) DK0378518T3 (en)
ES (1) ES2064700T3 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (en) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient
US5646265A (en) * 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ES2095960T3 (en) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int COMPOUNDS THAT HAVE ANTI-HYPERTENSIVE AND ANTI-ISCHEMICAL PROPERTIES.
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US5965722A (en) 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5206222A (en) * 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
AU4772493A (en) * 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (en) 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
DE69910213T2 (en) 1998-06-23 2004-07-01 Glaxo Group Ltd., Greenford 2- (PURIN-9-YL) -TETRAHYDROFURAN-3,4-DIOL DERIVATIVES
JP3619017B2 (en) 1998-06-24 2005-02-09 日本臓器製薬株式会社 New arabinosyladenine derivatives
ATE266662T1 (en) * 1998-07-22 2004-05-15 Daiichi Suntory Pharma Co Ltd NF-KAPPA B INHIBITORS CONTAINING INDANDERIVATES AS THE ACTIVE INGREDIENTS
PE20060272A1 (en) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
PA8663501A1 (en) 2005-02-17 2006-11-09 Wyeth Wyeth DERIVATIVES OF INDOL, BENZOTIOFEN, BENZOFURAN AND INDENO CICLOALQUILCONDENSADOS
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN100355769C (en) * 2005-11-16 2007-12-19 华东师范大学 2'-methoxy adenosine preparation method
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471472A (en) * 1966-10-20 1969-10-07 Boehringer & Soehne Gmbh N6-substituted adenosine derivatives
US3838147A (en) * 1971-04-10 1974-09-24 Merck Patent Gmbh Adenosine derivatives
US3845035A (en) * 1971-07-22 1974-10-29 Boehringer Mannheim Gmbh Novel n(6)-substituted adenosine compounds and therapeutic compositions
US3922261A (en) * 1972-06-21 1975-11-25 Merck Patent Gmbh Adenosine derivative
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
US4614732A (en) * 1984-10-26 1986-09-30 Warner-Lambert Company N6 -acenaphthyl adenosines and analogs thereof
US4616003A (en) * 1984-10-26 1986-10-07 Warner-Lambert Company N6 -dihydroxypropyladenosines
US4626526A (en) * 1984-10-26 1986-12-02 Warner-Lambert Company (S)-N6 -2-hydroxypropyladenosines
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
EP0269574A2 (en) * 1986-11-27 1988-06-01 Nippon Zoki Pharmaceutical Co. Ltd. Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
US4837207A (en) * 1987-05-13 1989-06-06 Warner-Lambert Company Diastereoisomers of n6 -endo-bicyclo[2.2.1]heptyladenosine as antihypertensives with selective action
US4985409A (en) * 1989-01-11 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine derivatives and pharmaceutical composition thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2628202A1 (en) * 1976-06-23 1977-12-29 Max Planck Gesellschaft PROCESS FOR THE PREPARATION OF 2'-SUBSTITUTE-D-RIBOFURANOSYLPURINE DERIVATIVES
AU579412B2 (en) * 1984-10-26 1988-11-24 Warner-Lambert Company N` - substituted adenosines
US4593019A (en) * 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
ZA857998B (en) * 1984-10-26 1986-05-28 Warner Lambert Co N6-substituted adenosines
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
JPS61103892A (en) * 1984-10-26 1986-05-22 ワーハー‐ランバート・コンパニー N6-acenaphthyladenosines and analogues
CA1255297A (en) * 1984-10-26 1989-06-06 Bharat Trivedi N.sup.6-benzopyrano and benzothiopyrano adenosines
ZA858154B (en) * 1984-10-26 1986-06-25 Warner Lambert Co N6-substituted deoxyribose analogs of adenosines
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471472A (en) * 1966-10-20 1969-10-07 Boehringer & Soehne Gmbh N6-substituted adenosine derivatives
US3838147A (en) * 1971-04-10 1974-09-24 Merck Patent Gmbh Adenosine derivatives
US3845035A (en) * 1971-07-22 1974-10-29 Boehringer Mannheim Gmbh Novel n(6)-substituted adenosine compounds and therapeutic compositions
US3922261A (en) * 1972-06-21 1975-11-25 Merck Patent Gmbh Adenosine derivative
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
US4616003A (en) * 1984-10-26 1986-10-07 Warner-Lambert Company N6 -dihydroxypropyladenosines
US4626526A (en) * 1984-10-26 1986-12-02 Warner-Lambert Company (S)-N6 -2-hydroxypropyladenosines
US4614732A (en) * 1984-10-26 1986-09-30 Warner-Lambert Company N6 -acenaphthyl adenosines and analogs thereof
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
EP0269574A2 (en) * 1986-11-27 1988-06-01 Nippon Zoki Pharmaceutical Co. Ltd. Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US4837207A (en) * 1987-05-13 1989-06-06 Warner-Lambert Company Diastereoisomers of n6 -endo-bicyclo[2.2.1]heptyladenosine as antihypertensives with selective action
US4985409A (en) * 1989-01-11 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine derivatives and pharmaceutical composition thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Goodman, "Chemical Syntheses and Transformations of Nucleosides", in Basic Principles in Nucleic Acid Chemistry, P.O.P.Ts'O ed., Academic Press, New York, 1974, see p. 144. *
Goodman, L., "Chemical Syntheses and Transformations of Nucleosides," Ch. 2 in Basic Principles in Nucleic Acid Chemistry, vol. 1, Ts'o (ed.), Academic Press, New York, 1974, pp. 93 and 144. *
Kikugawa et al., "Platelet Aggregation Inhibitors. 4. N6-Substituted Adenosines," J. Medicinal Chem., 16(4), 358-364 (1973). *
Kikugawa et al., J. Med. Chem., 16(4), 358-364 (1973). *
Robins et al., "Sugar Modified N6-(3-Methyl-2-butenyl)adenosine Derivatives, N6-Benzyl Analogs, and Cytokinin-Related Nucleosides Cotanining Sulfur or Formycin," Biochemistry, 12(12), 2179-2187 (1973). *

Also Published As

Publication number Publication date
ES2064700T3 (en) 1995-02-01
EP0378518A3 (en) 1990-12-27
ATE112285T1 (en) 1994-10-15
US4985409A (en) 1991-01-15
DK0378518T3 (en) 1994-10-24
EP0378518B1 (en) 1994-09-28
EP0378518A2 (en) 1990-07-18
DE69012840T2 (en) 1995-03-16
JPH0725785B2 (en) 1995-03-22
DE69012840D1 (en) 1994-11-03
JPH02184696A (en) 1990-07-19

Similar Documents

Publication Publication Date Title
USRE37077E1 (en) Adenosine derivatives and pharmaceutical composition thereof
US4843066A (en) Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US4225591A (en) 2,6-Diaminonebularines
CA1230595A (en) N.sup.6-(1- and 2-benzocycloalkyl)adenosines
JPH01265100A (en) 2-substituted adenosine derivatives
JPS6215062B2 (en)
EP0361831B1 (en) Antiviral nucleoside combination
EP0180190B1 (en) 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
HK87696A (en) Indolyl propanols, process for their preparation, their uses and preparation containing them
JP2001515900A (en) Antiviral drugs
US4258033A (en) 2,6-Diaminonebularines
EP0411912A2 (en) Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders
EP0154494A2 (en) Phenylimidazole inotropic agents
US4843093A (en) Butyrolactone derivatives, process for production thereof and use therefor
JPH0643421B2 (en) Pyrimidine derivative
US3984557A (en) Antiarrhythmia compositions and methods
RU2114839C1 (en) 2,3,4,5-tetrahydro-1h-3-benzazepines, pharmaceutical composition, method of treatment and methods of synthesis
EP0605728A1 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
JPH0686436B2 (en) Novel hydantoin derivative and pharmaceutical composition containing the compound
US3988317A (en) Heterocyclic-substituted nebularin compounds
US4015002A (en) 1-Aryl-2-oxo-2,4,5,6,7,7a-hexahydro-indoles, salts, pharmaceutical compositions and methods of use
JPH0615553B2 (en) Dihydropyridine-5-phosphonamidic acids
EP0072761B1 (en) Decarboxylase-inhibiting fluorinated alkane diamine derivatives
JPH0621073B2 (en) Central depressant
CN1147815A (en) Adenosine derivatives

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12